DFCI Logo
DFCI Logo
Wayne A. Marasco, MD, PhD

Wayne A. Marasco, MD, PhD

Researcher
MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-2153

Fax

617-632-3889

On This Page

Biography

Wayne A. Marasco, MD, PhD

Dr. Marasco received his PhD in 1980 from the University of Connecticut School of Medicine and postdoctoral training at the University of Michigan Medical School, where he also earned an MD in 1986 and completed training in internal medicine. He received his subspecialty training in infectious diseases at Harvard Medical School, and joined DFCI in 1989. In 2003, he founded the National Foundation of Cancer Research Center for Therapeutic Antibody Engineering to expand the use of human monoclonal antibodies in the treatment of cancer. In 2009, he was listed among 13 top scientists in their field as the 21st century medicine "Pioneeers of Medicine Progress" by US News & World report. He is head of an accomplished research laboratory in the area of cancer and infectious disease immunotherapy.

Researcher

Physician

Principal Investigator, Cancer Immunology and Virology, Dana-Farber Cancer Institute
Professor of Medicine, Brigham and Women’s Hospital

Centers/Programs

Recent Awards

  • "Pioneer of Medical Progress", U.S. News & World Report (among 13 top scientists in their field)

    2009

Research

    View Dr. Marasco’s Research

    Human monoclonal antibody-based immunotherapy

    Our laboratory focuses on the engineering and use of human antibodies in discovery research and disease treatment. We are working in three disease areas: cancer, emerging infectious diseases, and HIV/AIDS – a breadth of investigation made possible by the development and use of state-of-the-art tools in the field of antibody engineering that support our research efforts. More recently, we have been developing humanized mice to support our targeted immunotherapy studies and to investigate the roles of human adult stem cells in regenerative medicine.

    We have active research programs in cancer immunotherapy that include the following targets: CXCR4 for breast cancer, G250 (CA IX) for renal cell carcinoma, CCR4 for cutaneous T cell lymphomas (CTCLs), and IGHV1-69 encoded B-cell receptors (BCR) for treatment of an aggressive form of chronic lymphocytic leukemia (CLL). We are also developing immunotherapies that can modulate immune T cell activity to boost natural cancer immunity and response to cancer vaccines. Regulatory T cells (Tregs) exert control by dampening the immune response to prevent host tissue damage, but these cells are also co-opted by cancer cells, which leads to immune evasion. Tregs express high levels of CCR4 and we have demonstrated in vitro and in vivo that anti-CCR4 Mabs can reverse this immune suppression and reverse T cell "exhaustion," thereby restoring host immunity.

    We use human monoclonal antibodies in functional and structural studies to understand mechanisms of viral entry; identify common targets that provide broad-spectrum protection; and develop strategies that prevent the viruses from undergoing neutralization escape. Vaccinated/infected humans and humanized mice are the B-cell sources of antibody genes for these studies. We are studying human pathogenic viruses that include influenza A, West Nile Virus, SARS- and MERS-CoVs and HIV/AIDS. As with our cancer studies, we are investigating whether human antibodies that are directed to surface proteins on T-cells or their secreted products can reverse T-cell "exhaustion" which is known to occur in HIV-1/AIDS with the goal of lowering viral loads, prolonging health, and preventing the spread of HIV-1. We are using our humanized mice in the area of anti-microbial immunity to develop broad-spectrum anti-viral vaccines.

    Research Departments

    Support my research

    Research Website

    http://marascolab.dana-farber.org

    Publications

      View Dr. Marasco's Publications

      • Genetic variation in the immunoglobulin heavy chain locus shapes the human antibody repertoire. Nat Commun. 2023 07 21; 14(1):4419. View in: Pubmed

      • The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility. Protein Eng Des Sel. 2023 Jan 21; 36. View in: Pubmed

      • IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nat Commun. 2022 10 03; 13(1):5814. View in: Pubmed

      • Preclinical models for development of immune-oncology therapies. Immuno-oncol Insights. 2022; 3(8):379-398. View in: Pubmed

      • Immune Evasion of SARS-CoV-2 Omicron Subvariants. Vaccines (Basel). 2022 Sep 16; 10(9). View in: Pubmed

      • Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells. Int J Mol Sci. 2022 May 13; 23(10). View in: Pubmed

      • Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. EBioMedicine. 2022 Jun; 80:104025. View in: Pubmed

      • Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y. J Virol. 2022 03 23; 96(6):e0198221. View in: Pubmed

      • Anti-CAIX BB? CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. Mol Ther Oncolytics. 2022 Mar 17; 24:385-399. View in: Pubmed

      • Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses. Nat Commun. 2021 01 25; 12(1):559. View in: Pubmed

      • Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease. Clin Chem. 2020 12 01; 66(12):1562-1572. View in: Pubmed

      • High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity Assays. Cytometry A. 2021 07; 99(7):689-697. View in: Pubmed

      • A Novel Framework for Characterizing Genomic Haplotype Diversity in the Human Immunoglobulin Heavy Chain Locus. Front Immunol. 2020; 11:2136. View in: Pubmed

      • Author Correction: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2020 Jul; 26(7):1146. View in: Pubmed

      • A New Humanized Mouse Model Mimics Humans in Lacking a-Gal Epitopes and Secreting Anti-Gal Antibodies. J Immunol. 2020 04 01; 204(7):1998-2005. View in: Pubmed

      • A high-throughput chemotaxis detection method for CCR4+ T cell migration inhibition using image cytometry. J Immunol Methods. 2020 04; 479:112747. View in: Pubmed

      • Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody. J Virol. 2019 01 15; 93(2). View in: Pubmed

      • Alcohol consumption increases susceptibility to pneumococcal pneumonia in a humanized murine HIV model mediated by intestinal dysbiosis. Alcohol. 2019 11; 80:33-43. View in: Pubmed

      • Synonymous Mutations at the Beginning of the Influenza A Virus Hemagglutinin Gene Impact Experimental Fitness. J Mol Biol. 2018 04 13; 430(8):1098-1115. View in: Pubmed

      • The latest animal models of ovarian cancer for novel drug discovery. Expert Opin Drug Discov. 2018 03; 13(3):249-257. View in: Pubmed

      • Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. Cell Rep. 2017 Dec 12; 21(11):3243-3255. View in: Pubmed

      • Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat. Vaccine. 2017 09 05; 35(37):5011-5018. View in: Pubmed

      • The Individual and Population Genetics of Antibody Immunity. Trends Immunol. 2017 07; 38(7):459-470. View in: Pubmed

      • A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016 Nov 28; 2:16226. View in: Pubmed

      • Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates. Am J Trop Med Hyg. 2016 Nov 02; 95(5):1148-1156. View in: Pubmed

      • A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve. Nat Commun. 2016 09 13; 7:12780. View in: Pubmed

      • Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016 Jun 07; 7(23):34341-55. View in: Pubmed

      • Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016 04 29; 6:23876. View in: Pubmed

      • Corrigendum: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2016 Apr; 22(4):446. View in: Pubmed

      • SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):3048-53. View in: Pubmed

      • Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. MAbs. 2016 May-Jun; 8(4):787-98. View in: Pubmed

      • IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016 Feb 16; 6:20842. View in: Pubmed

      • 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016 03; 490:49-58. View in: Pubmed

      • Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075. View in: Pubmed

      • A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015 Dec; 21(12):1508-13. View in: Pubmed

      • Reconstitution of the receptor-binding motif of the SARS coronavirus. Protein Eng Des Sel. 2015 Dec; 28(12):567-75. View in: Pubmed

      • Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy. Immunotherapy. 2015; 7(6):591-4. View in: Pubmed

      • Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol Cancer. 2015 Jun 11; 14:119. View in: Pubmed

      • Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme. J Virol. 2015 Jul; 89(14):7202-13. View in: Pubmed

      • Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood. 2015 Jun 18; 125(25):3886-95. View in: Pubmed

      • Phage and Yeast Display. Microbiol Spectr. 2015 Feb; 3(1):AID-0028-2014. View in: Pubmed

      • Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor. Mol Ther Oncolytics. 2014; 1:14003. View in: Pubmed

      • Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages. J Neuroinflammation. 2014 Nov 22; 11:195. View in: Pubmed

      • Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol. 2014 Dec; 88(23):13769-80. View in: Pubmed

      • Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer. Gene Ther. 2014 Sep; 21(9):802-10. View in: Pubmed

      • Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 2014 May; 10(5):e1004103. View in: Pubmed

      • Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014 May 13; 111(19):E2018-26. View in: Pubmed

      • Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs. 2014 May-Jun; 6(3):577-618. View in: Pubmed

      • Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry. Stem Cells Transl Med. 2013 Aug; 2(8):567-78. View in: Pubmed

      • Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J. 2013 Feb; 27(2):581-9. View in: Pubmed

      • Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS One. 2012; 7(9):e44455. View in: Pubmed

      • In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat. Hum Gene Ther. 2012 Sep; 23(9):917-31. View in: Pubmed

      • Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis. 2012; 2012:463569. View in: Pubmed

      • Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther. 2012 Nov; 11(11):2451-61. View in: Pubmed

      • Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol. 2012 Oct; 50(10):3216-21. View in: Pubmed

      • Human B-cell ontogeny in humanized NOD/SCID ?c(null) mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. Genes Immun. 2012 Jul; 13(5):399-410. View in: Pubmed

      • Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology. 2011 Dec; 134(4):419-33. View in: Pubmed

      • Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One. 2011; 6(10):e26473. View in: Pubmed

      • Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display. Biochem Biophys Res Commun. 2011 Jun 03; 409(2):253-9. View in: Pubmed

      • Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011 Apr 15; 52(8):1003-9. View in: Pubmed

      • Structural basis of influenza virus neutralization. Ann N Y Acad Sci. 2011 Jan; 1217:178-90. View in: Pubmed

      • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011 Jan 17; 208(1):181-93. View in: Pubmed

      • Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun. 2010 Dec 10; 403(2):247-51. View in: Pubmed

      • Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. J Immunol. 2010 Dec 15; 185(12):7623-32. View in: Pubmed

      • Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer. 2010 Aug 01; 127(3):598-611. View in: Pubmed

      • Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One. 2010 Mar 10; 5(3):e9625. View in: Pubmed

      • Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2010 Mar; 5(1):81-93. View in: Pubmed

      • Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol. 2009 Jul 01; 183(1):650-60. View in: Pubmed

      • Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther. 2009 Jun; 20(6):554-62. View in: Pubmed

      • Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009 Mar; 16(3):265-73. View in: Pubmed

      • Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol. 2009 Jan; 85(1):165-74. View in: Pubmed

      • Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 2008 Nov; 4(11):e1000197. View in: Pubmed

      • Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS One. 2008 Sep 11; 3(9):e3181. View in: Pubmed

      • Influenza A virus neuraminidase limits viral superinfection. J Virol. 2008 May; 82(10):4834-43. View in: Pubmed

      • The Collection, Processing and Storage of Adult Stem Cells – A Bio-Insurance Policy for Personalized Medical Therapies. Life Extension Foundation magazine. 2008. View in: Pubmed

      • Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol. 2008; (181):343-73. View in: Pubmed

      • The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007 Dec; 25(12):1421-34. View in: Pubmed

      • Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol. 2007 Aug 15; 179(4):2408-18. View in: Pubmed

      • The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology. 2007 Oct 25; 367(2):367-74. View in: Pubmed

      • Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. Blood. 2007 Sep 15; 110(6):2110-20. View in: Pubmed

      • Intracellular antibodies (Intrabodies) as specific molecules for therapeutic applications. In Handbook of Experimental Pharmacology. Chernajovsky Y, ed. 2007. View in: Pubmed

      • Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem. 2006 Nov 10; 281(45):34610-6. View in: Pubmed

      • Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol. 2006 Nov; 80(22):11000-8. View in: Pubmed

      • Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 2006 Oct 06; 348(4):1245-53. View in: Pubmed

      • Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther. 2006 Aug; 5(8):2096-105. View in: Pubmed

      • Convergent Combination Immunotherapy for the Prevention and Treatment of SARS. The 5th International Congress on Recombinant Antibodies. Zurich, Switzerland. 2006. View in: Pubmed

      • Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A. 2006 May 09; 103(19):7454-9. View in: Pubmed

      • Passive immunotherapy in an outbreak setting. A case of SARS. From Concept to Clinic. Cambridge Health Institute’s 7th Annual Meeting, Boston, MA. 2006. View in: Pubmed

      • Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol. 2006 May 26; 359(1):190-201. View in: Pubmed

      • Immunopathogenesis and Immunotherapy of SARS. In Challenges of Severe Acute Respiratory Syndrome. Chan JCK and Wong VCW, eds. 2006. View in: Pubmed

      • Human neutralizing antibodies for convergent immunotherapy against SARS. 16th Annual International Conference on Antibody Engineering, San Diego, CA. 2005. View in: Pubmed

      • Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol. 2005 Dec; 79(23):14606-13. View in: Pubmed

      • A strategy to move potent neutralizing anti-SARS monoclonal antibodies into clinical trials in an outbreak setting. The Second China International Symposium on Antibody Engineering. Invited Speaker. Therapeutic Antibodies for Non-Malignant Diseases. Beijing, China,. 2005. View in: Pubmed

      • A Strategy Toward Convergent Combination Immunotherapy for SARS. ICLAS-CALAS International Symposium. Animal Models of Infectious Diseases. Beijing, China. 2005. View in: Pubmed

      • Development of Renal Cell Carcinoma (RCC) Vaccine against G250 by Co-Expression of G250 Extracellular Domain-Fc Fusion Protein and IL-2 Using 2A Self-Processing Peptide. CHI Conference. Cancer Immunotheerptics and Targeted Cancer Therapies, Boston, MA. 2005. View in: Pubmed

      • Role of HTLV-1 Tax in SH2-containing Tyrosine Phosphatase-1 (SHP-1) Promoter Silencing in Acute Infection and Adult T-Cell Leukemia. 12th International Conference on Human Retrovirology: HTLV-1 and Related Viruses. Montego Bay, Jamaica. 2005. View in: Pubmed

      • Suppresses Shp-1 (SH2-containing Tyrosine Phosphatase-1) Gene Expression and Facilitates Leukemogenesis Through Tax-Promoter Interaction. 12th International Conference on Human Retrovirology: HTLV-1 and Related Viruses. Montego Bay, Jamaica. 2005. View in: Pubmed

      • An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol. 2005 Jul; 206(3):251-9. View in: Pubmed

      • GITR overexpression on CD4+CD25+ HTLV-1 transformed cells: detection by massively parallel signature sequencing. Biochem Biophys Res Commun. 2005 Jul 01; 332(2):569-84. View in: Pubmed

      • Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005 Jun; 23(6):709-17. View in: Pubmed

      • Therapeutic antibody gene transfer. Nat Biotechnol. 2005 May; 23(5):551-2. View in: Pubmed

      • Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol. 2005 May; 79(10):5900-6. View in: Pubmed

      • Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005 Apr 20; 24(8):1634-43. View in: Pubmed

      • Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005 Mar 15; 65(6):2344-52. View in: Pubmed

      • Role of SHP-1 deregulation in HTLV-1 leukemogenesis. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2005. View in: Pubmed

      • Potential Use of Human Monoclonal Antibodies Against CXCR4 for the Prevention and Treatment of Breast Cancer Metastasis. Keystone Symposium on Antibody Based Therapeutics for Cancer, Santa Fe, NM. 2005. View in: Pubmed

      • T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 2005 Feb; 12(4):299-310. View in: Pubmed

      • A strategy for Global Collaborations to Develop Human Monoclonal Antibody (mAb) Drugs for the Treatment of Cancer. Oncology Research. 2005; 15:458. View in: Pubmed

      • Preventive and therapeutic immunization against lethal murine West Nile virus infection with a bivalent human single-chain antibody (scFv)-Fc fusion protein and rabbit polyclonal antibody against the envelope protein. American Association of Tropical Medicine and Hygiene Annual Meeting, Miami Beach, FL. 2004. View in: Pubmed

      • Targeting Dendritic Cells: Selection of Single Chain Antibodies from a Human Phage Display Library. The 12th Annual Congress of the European Society of Gene Therapy, Tampere, Finland. 2004. View in: Pubmed

      • MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies--a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods. 2004 Oct; 34(2):240-9. View in: Pubmed

      • Isolation of human antibodies against CXCR4 by paramagnetic proteoliposomes for prevention and treatment of breast cancer metastases. The Susan G, Komen Cancer Foundation Pathways to a Promise. New York, NY. 2004. View in: Pubmed

      • Transcriptional deregulation in adult T-cell leukemia: Genome-wide transcriptional profiling of acutely HTLV-1 transformed cells using Massively Parallel Signature Sequencing. 95th AACR Annual Meeting, Orlando, FL. 2004. View in: Pubmed

      • Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8):2536-41. View in: Pubmed

      • Abrogation of Fibroblast Activation Protein Enzymatic Activity Attenuates Tumor Growth. AACR Annual Meeting, Dana Point, CA. 2004. View in: Pubmed

      • Role of SHP-1 deregulation in HTLV-1 leukemogenesis. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. 2004. View in: Pubmed

      • Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol. 2004 Jan 02; 335(1):193-207. View in: Pubmed

      • Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells. Leuk Res. 2004 Jan; 28(1):71-82. View in: Pubmed

      • Identification of CD4 and transferrin receptor antibodies by CXCR4 antibody-guided Pathfinder selection. Eur J Biochem. 2003 Nov; 270(22):4497-506. View in: Pubmed

      • Fatal Fulminant Hepatic Failure from Adenovirus in Allogeneic Bone Marrow Transplant Patients. 41st Annual Meeting of Infectious Diseases Society of America. 2003. View in: Pubmed

      • Breakthrough Zygomycosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients Who Received Voriconazole as Prophylaxis or Empiric Therapy. 43rd ICAAC. 2003. View in: Pubmed

      • Down-Regulation of SHP1 and Up-Regulation of Negative Regulators of JAK/STAT Signaling in HTLV-1 Transformed Cell Lines and Freshly Transformed Human Peripheral Blood CD4+ T-cells. 3rd Annual Harvard Medical School Centers for AIDS Research Symposium, Boston, MA. 2003. View in: Pubmed

      • Generation and Characterization of Engineered Human Anti-CCR5 Antibodies. 3rd Annual Harvard Medical School Centers for AIDS Research Symposium, Boston, MA. 2003. View in: Pubmed

      • Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J Acquir Immune Defic Syndr. 2003 Mar 01; 32(3):245-54. View in: Pubmed

      • Intrabodies as Tools to Perturb Cellular Function. Guest Speaker for the Antibody-Based Therapeutics for Cancer, 2003 Keystone Symposia. 2003. View in: Pubmed

      • Intracellular targeting of antibodies in mammalian cells. In New Comprehensive Biocehmistry : Gene Transfer and Expression in Mammalian Cells. Savvas C. Makrides , ed. 2003; 573 – 623. View in: Pubmed

      • Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology. 2002 Nov 10; 303(1):9-14. View in: Pubmed

      • Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem. 2003 Jan 17; 278(3):1433-42. View in: Pubmed

      • Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther. 2002 Mar; 9(5):307-19. View in: Pubmed

      • Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation. Biochem Biophys Res Commun. 2001 Aug 24; 286(3):587-94. View in: Pubmed

      • Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 2001 Aug; 8(8):555-65. View in: Pubmed

      • Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Mol Med. 2001 Aug; 7(8):569-79. View in: Pubmed

      • Intrabodies as antiviral agents. Curr Top Microbiol Immunol. 2001; 260:247-70. View in: Pubmed

      • Intrabodies as anti-viral agents. In Current Topics in Microbiology and Immunology. Dennis R. Burton,ed. 2001; 260:247-70. View in: Pubmed

      • Expression vectors and methods of use. 2000. View in: Pubmed

      • Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc. J Biol Chem. 2000 Oct 06; 275(40):30925-33. View in: Pubmed

      • Upregulation of the apoptosis-associated protein Grb3-3 in HIV-1-infected human CD4(+) lymphocytes. Biochem Biophys Res Commun. 2000 Sep 16; 276(1):362-70. View in: Pubmed

      • Method of intracellular binding of target molecules. 2000. View in: Pubmed

      • Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol. 2000 Jun; 18(6):649-54. View in: Pubmed

      • Rapid establishment of myeloma cell lines expressing Fab (Tac)-Protamine, A targetable protein vector, directed against the high affinity alpha chain of the human interleukin-2 receptor. In Methods in Molecular Biology. Eric Kmiec, ed. 2000; 133:156-66. View in: Pubmed

      • Rapid establishment of myeloma cell lines expressing Fab(Tac)-protamine, a targetable protein vector, directed against high-affinity alpha-chain of human interleukin-2 receptor. Methods Mol Biol. 2000; 133:157-66. View in: Pubmed

      • Intracellular targeting of endogenous proteins. 1999. View in: Pubmed

      • Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods. 1999 Dec 10; 231(1-2):223-38. View in: Pubmed

      • Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods. 1999 Dec 10; 231(1-2):207-22. View in: Pubmed

      • Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum Gene Ther. 1999 Oct 10; 10(15):2505-14. View in: Pubmed

      • Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther. 1999 Jun 10; 10(9):1453-67. View in: Pubmed

      • Reactive neutralizing human anti-gp120 recombinant antibody, DNA coding the same and use thereof. 1998. View in: Pubmed

      • Method of intracellular binding of target molecules. 1998. View in: Pubmed

      • Method of intracellular binding of target molecules. 1998. View in: Pubmed

      • Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther. 1998 Jul 20; 9(11):1627-42. View in: Pubmed

      • Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 1998 May; 5(5):635-44. View in: Pubmed

      • Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Adv Drug Deliv Rev. 1998 Apr 06; 31(1-2):153-170. View in: Pubmed

      • The therapeutic potential of intracellular antibodies. BioDrugs. 1998 Mar; 9(3):179-85. View in: Pubmed

      • Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther. 1998 Mar 01; 9(4):487-96. View in: Pubmed

      • Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS. Am J Pathol. 1998 Jan; 152(1):167-78. View in: Pubmed

      • Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. In Advanced Drug Reviews. 1998; 31:153-170. View in: Pubmed

      • Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. Virology. 1997 Oct 27; 237(2):209-16. View in: Pubmed

      • Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol. 1997 Sep; 71(9):6486-94. View in: Pubmed

      • Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med. 1997 Feb; 3(2):96-110. View in: Pubmed

      • Intrabodies targeted against regulatory epitopes of HIV-1: Tat and Rev as two significant targets for gene therapy. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997. View in: Pubmed

      • Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 1997 Jan; 4(1):11-5. View in: Pubmed

      • Studies on the phenotypic ¡§knockout¡¨ of the human interleukin-2 receptor ƒÑ chain. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997. View in: Pubmed

      • Designing Intrabodies: Structural features and the use of intracellular trafficking signals. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997. View in: Pubmed

      • Intrabodies: From antibody genes to intracellular immunization. In The Antibodies, Zanetti M and Capra JD, eds. 1997; 4. View in: Pubmed

      • Gene therapy for HIV-1 using intracellular antibodies against HIV-1 Gag proteins. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997. View in: Pubmed

      • The therapeutic potential of intracellular antibodies. In BioDrugs. Beedle AS, ed. 1997. View in: Pubmed

      • Intracellular antibodies (intrabodies): Potential applications in transgenic animal research and engineered resistance to pathogens. In Transgenic Animals - Generation and Use. Houdebine L-M, ed. . 1997; 74:501-6. View in: Pubmed

      • Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol. 1997; 51:257-83. View in: Pubmed

      • Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther. 1996 Aug 20; 7(13):1515-25. View in: Pubmed

      • Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol. 1996 Feb; 23(1):148-53. View in: Pubmed

      • Intrabody-based gene therapy approaches against HIV-1. In -Advancing a New Agenda for AIDS Research, Poznansky M.C., Coker R.J. and Gilles P., eds. 1996. View in: Pubmed

      • Gene Therapy and Research Applications of Intrabodies for Human Infectious Diseases. In The Use of Ectopic Antibody Expression for Intracellular and Extracellular Immunization. Biocca S. And Cattaneo A., eds. 1996. View in: Pubmed

      • Looking ahead: Combination of intracellular single-chain antibodies and other genetic-based anti-HIV-1 approaches hold promise as an effective strategy for AIDS gene therapy. In Drugs, News and Perspectives. 1996; 9:220-7. View in: Pubmed

      • Intracellular antibodies: development and therapeutic potential. Trends Biotechnol. 1995 Aug; 13(8):306-10. View in: Pubmed

      • Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology. 1995 May; 1(1):1-19. View in: Pubmed

      • Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A. 1995 Apr 11; 92(8):3137-41. View in: Pubmed

      • Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 1995 Apr 03; 14(7):1542-51. View in: Pubmed

      • Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 1995 Mar; 2(2):116-23. View in: Pubmed

      • Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest. 1995 Feb; 95(2):732-7. View in: Pubmed

      • Gene therapy. In HIV: A Practical Approach: Volume 2, Biochemistry, Molecular Biology, Drug Discovery. Karn J, ed. 1995. View in: Pubmed

      • Intracellular antibodies for HIV-1 gene therapy. In Expert Opinion on Investigational Drugs. 1995; 4:823-31. View in: Pubmed

      • Chemotaxis and activation of neutrophils. In Symposium on Chemical Mediators of Inflammation. Japan, Cohen S, Hayashi H, Saito K, and Takada A. eds. 1995; 220-4. View in: Pubmed

      • Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol. 1994 Oct; 31(15):1149-60. View in: Pubmed

      • Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A. 1994 Jun 21; 91(13):5932-6. View in: Pubmed

      • Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther. 1994 May; 5(5):595-601. View in: Pubmed

      • Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch Virol. 1994; 139(1-2):133-54. View in: Pubmed

      • Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993 Aug 15; 90(16):7889-93. View in: Pubmed

      • Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest. 1992 Oct; 90(4):1467-78. View in: Pubmed

      • Acquired immunodeficiency syndrome with disseminated toxoplasmosis presenting as an acute pulmonary and gastrointestinal illness. Arch Pathol Lab Med. 1991 May; 115(5):459-63. View in: Pubmed

      • Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis. 1991 Mar-Apr; 13(2):270-80. View in: Pubmed

      • Characterization of a class of nonformylated Enterococcus faecalis-derived neutrophil chemotactic peptides: the sex pheromones. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):66-70. View in: Pubmed

      • Unusual presentation of cat scratch disease in a patient positive for antibody to the human immunodeficiency virus. Rev Infect Dis. 1989 Sep-Oct; 11(5):793-803. View in: Pubmed

      • Autoradiographic analysis of formylpeptide chemoattractant binding, uptake and intracellular processing by neutrophils. J Cell Sci. 1989 Sep; 94 ( Pt 1):155-68. View in: Pubmed

      • Regulation of formyl peptide receptor binding to rabbit neutrophil plasma membranes. Use of monovalent cations, guanine nucleotides, and bacterial toxins to discriminate among different states of the receptor. J Immunol. 1989 Jun 01; 142(11):3963-70. View in: Pubmed

      • Recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) regulates f Met-Leu-Phe receptors on human neutrophils. Immunology. 1988 Jul; 64(3):519-25. View in: Pubmed

      • Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest. 1988 Mar; 81(3):759-65. View in: Pubmed

      • Chemotactic factors of bacterial origin. Methods Enzymol. 1988; 162:198-214. View in: Pubmed

      • Chemotactic factors of bacterial origin. Chapter 19. In Immunological Techniques. Part L. Chemotaxis and Inflammation. Methods in Enzymology. DiSabato G, Langone JJ, and VanVunakis H, eds. 1988; Vol. 162:198-214. View in: Pubmed

      • Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria. Arch Intern Med. 1987 Dec; 147(12):2107-16. View in: Pubmed

      • Direct visualization of formylpeptide receptor binding on rounded and polarized human neutrophils: cellular and receptor heterogeneity. J Leukoc Biol. 1987 May; 41(5):377-91. View in: Pubmed

      • Heterogeneity and topographical asymmetry of formyl peptide receptor binding on polymorphonuclear leukocytes. In The Biology of Phagocytes in Health and Disease. Mauri C, Rizzo SC, and Ricevuti G, eds. 1987; 9-21. View in: Pubmed

      • Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors. J Immunol. 1986 Sep 15; 137(6):1961-70. View in: Pubmed

      • Inhibition of neutrophil activation by p-bromophenacyl bromide and its effects on phospholipase A2. Br J Pharmacol. 1986 Jun; 88(2):463-72. View in: Pubmed

      • Covalent affinity labeling, detergent solubilization, and fluid-phase characterization of the rabbit neutrophil formyl peptide chemotaxis receptor. Biochemistry. 1985 Apr 23; 24(9):2227-36. View in: Pubmed

      • Chemotactic factor binding by metastatic tumour cells: evidence for a formyl-peptide receptor on a non-myelogenous cell. J Cell Sci. 1985 Feb; 73:121-34. View in: Pubmed

      • A search for "Internal Image" anti-idiotypic antibodies: A subpopulation of anti-f Met-Leu-Phe anti-idiotypic antibodies binds to the formyl peptide chemotaxis receptor of the neutrophil and to several genetically unrelated anti-f Met-Leu-Phe antibodies. In UCLA Symposium on Molecular and Cellular Biology. New Series, Reisfeld RA and Sell S. eds. 1985; 27:327-44. View in: Pubmed

      • Formyl peptide chemotaxis receptors on the rat neutrophil: experimental evidence for negative cooperativity. J Cell Biochem. 1985; 27(4):359-75. View in: Pubmed

      • What are the molecular characteristics of the neutrophil receptor for chemotactic formylated peptides? Surv Immunol Res. 1985; 4(3):213-9. View in: Pubmed

      • Localization of chemotactic peptide receptors on rabbit neutrophils. Exp Cell Res. 1984 Oct; 154(2):613-8. View in: Pubmed

      • Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem. 1984 May 10; 259(9):5430-9. View in: Pubmed

      • Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol. 1984 Apr; 115(1):9-16. View in: Pubmed

      • A specific enzyme-linked immunosorbent assay (ELISA) for the determination of human C5a antigen. J Immunol Methods. 1983 Sep 16; 62(3):305-14. View in: Pubmed

      • Characterization of the rat neutrophil formyl peptide chemotaxis receptor. Am J Pathol. 1983 Jun; 111(3):273-81. View in: Pubmed

      • Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil. J Immunol. 1983 Apr; 130(4):1495-7. View in: Pubmed

      • Spasmogenic activity of chemotactic N-formylated oligopeptides: identity of structure--function relationships for chemotactic and spasmogenic activities. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7470-3. View in: Pubmed

      • Anti-idiotype as antibody against the formyl peptide chemotaxis receptor of the neutrophil. J Immunol. 1982 Feb; 128(2):963-8. View in: Pubmed

      • Anti-f Met-Leu-Phe: similarities in fine specificity with the formyl peptide chemotaxis receptor of the neutrophil. J Immunol. 1982 Feb; 128(2):956-62. View in: Pubmed

      • Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun. 1981 Apr 30; 99(4):1065-72. View in: Pubmed

      • The ionic basis of chemotaxis. Separate cation requirements for neutrophil orientation and locomotion in a gradient of chemotactic peptide. Am J Pathol. 1980 Mar; 98(3):749-68. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Jimmy Fund 824 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Jimmy Fund 824 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Discovery and Insights

      Back to Top